[Abstract] Objective:To investigate the changes of interleukin-27and lymphotoxin-a in the patients with acute coronary syndrome (ACS). To explore the contribution in the development of ACS. Methods:Seventy-four patients with diagnosed ACS through coronary angiography (CAG) were divided into35cases of ST-segment elevation acute coronary syndrome (ST-ACS),39cases of non-ST-segment elevation acute coronary syndrome(NST-ACS) and13cases of normal angiography serves as control group. The serum concentrations both of interleukin-27and lymphotoxin-a in the patients with ACS were detected with enzyme linked immunosorbent assay way. According to the statistical results to explore the contribution of the two factors in the development of ACS. Results:(1) The serum concentrations of interleukin-27with ST-ACS was lower than in the patients with NST-ACS(25.01±7.97ng/ml vs59.47±9.77ng/ml, P<0.05), The serum concentrations of interleukin-27with ST-ACS was lower than in the person with coronary angiography normal group (25.01±7.97ng/ml vs106.74±33.43ng/ml, P<0.01). The serum concentrations of interleukin-27with NST-ACS group was lower than in the person with coronary angiography normal group(59.47±9.77ng/ml vs106.74±33.43ng/ml, P<0.01). Among the three groups pairwise comparisons were statistically significant.(2) The concentrations of the lymphotoxin-a in the patients with ST-ACS was higher than in the patients with NST-ACS(204.54±125.17ng/ml vs128.40±66.11ng/ml, P<0.05), The concentrations of the lymphotoxin-a in the patients with ST-ACS was higher than in the person with normal coronary angiography group(204.54±125.17ng/ml vs43.01±35.06ng/ml, P<0.01). The concentrations of the lymphotoxin-a in the patients with NST-ACS group was higher than in the person with normal coronary angiography group(128.40±66.11ng/ml vs43.01±35.06ng/ml, P<0.01). Pairwise comparisons among the three groups were statistically significant. Conclusions:(1) Interleukin-27may play the role of anti-inflammatory immune, it has the negative impact on the occurrence of ACS.(2) Lymphotoxin-a involved in the pathophysiological process of ACS, Lymphotoxin-a may promote coronary atherosclerotic plaque rupture and thrombosis in the patients with ACS. |